
Johnson & Johnson has announced that study 452, the second pivotal phase 3 study evaluating CAPLYTA (lumateperone) for the treatment of manic episodes with or without mixed features in adults with bipolar I disorder, met its primary and key secondary endpoints.
Caplyta significantly improved manic symptoms and overall illness severity versus placebo at week 3, with significant improvements observed as early as day three.
Together with the positive results from study 451, these findings provide consistent evidence across two pivotal phase 3 studies and will support the planned US regulatory submission.
Study 452 was a global, phase 3 randomised, double-blind study evaluating once-daily Caplyta 42 mg versus placebo over three weeks in adults with manic episodes, with or without mixed features, associated with bipolar I disorder.


